The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

European Journal of Cancer

Volumn 47, Issue 9, 2011, Pages 1373-1379

  Vrooman, Lynda M ^a,b   Neuberg, Donna S ^a   Stevenson, Kristen E ^a   Asselin, Barbara L ^c   Athale, Uma H ^d   Clavell, Luis ^e   Cole, Peter D ^f   Kelly, Kara M ^g   Larsen, Eric C ^h   Laverdire, Caroline ⁱ   Michon, Bruno ^j   Schorin, Marshall ^k   Schwartz, Cindy L ^l   Cohen, Harvey J ^m   Lipshultz, Steven E ⁿ   Silverman, Lewis B ^a,b   Sallan, Stephen E ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e San Jorge Children's Hospital   (Puerto Rico)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g NewYork Presbyterian Hospital   (United States)

^h Maine Children's Cancer Program Portland   (United States)

ⁱ UNIVERSITY OF MONTREAL   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k INOVA FAIRFAX HOSPITAL FOR CHILDREN   (United States)

^l BROWN UNIVERSITY   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acute lymphoblastic leukemia; Childhood leukemia; Dexrazoxane; Second malignant neoplasm; Secondary acute myelogenous leukemia

Indexed keywords

ASPARAGINASE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RAZOXANE; STEROID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CHILD; CLINICAL PROTOCOL; FOLLOW UP; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; METASTASIS; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARDIOTONIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASMS, SECOND PRIMARY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RAZOXANE; RISK; TIME FACTORS;

EID: 79957557043     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.03.022     Document Type: Article

References (43)

1. C.H. Pui, D. Campana, and D. Pei Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 360 26 2009 2730 2741
2. A. Moricke, A. Reiter, and M. Zimmermann Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 Blood 111 9 2008 4477 4489
3. C.D. Mitchell, S.M. Richards, and S.E. Kinsey Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial Br J Haematol 129 6 2005 734 745 (Pubitemid 40904523)
4. A.J. Veerman, W.A. Kamps, and H. van den Berg Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004) Lancet Oncol 10 10 2009 957 966
5. P.S. Gaynon, A.L. Angiolillo, and W.L. Carroll Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report Leukemia 24 2 2010 285 297
6. A. Moghrabi, D.E. Levy, and B. Asselin Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia Blood 109 3 2007 896 904 (Pubitemid 46220632)
7. A. Moricke, M. Zimmermann, and A. Reiter Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 Leukemia 24 2 2010 265 284
8. E.A. Lefrak, J. Pitha, S. Rosenheim, and J.A. Gottlieb A clinicopathologic analysis of adriamycin cardiotoxicity Cancer 32 2 1973 302 314
9. D.A. Mulrooney, M.W. Yeazel, and T. Kawashima Cardiac outcomes in a cohort of adult survivors of childhood, adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort BMJ 339 2009 b4606
10. E. Barry, J.A. Alvarez, R.E. Scully, T.L. Miller, and S.E. Lipshultz Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management Expert Opin Pharmacother 8 8 2007 1039 1058 (Pubitemid 46929299)
11. S.E. Lipshultz, R.E. Scully, and S.R. Lipsitz Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial Lancet Oncol 11 10 2010 950 961
12. S.M. Swain, F.S. Whaley, and M.C. Gerber Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J Clin Oncol 15 4 1997 1318 1332 (Pubitemid 27167363)
13. M. Lopez, P. Vici, and K. Di Lauro Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas J Clin Oncol 16 1 1998 86 92 (Pubitemid 28041583)
14. S.E. Lipshultz, N. Rifai, and V.M. Dalton The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med 351 2 2004 145 153 (Pubitemid 38886649)
15. C.K. Tebbi, W.B. London, and D. Friedman Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease J Clin Oncol 25 5 2007 493 500 (Pubitemid 350002954)
16. E.V. Barry, L.M. Vrooman, and S.E. Dahlberg Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane J Clin Oncol 26 7 2008 1106 1111
17. J. Zhou, M.A. Goldwasser, and A. Li Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood 110 5 2007 1607 1611 (Pubitemid 47443978)
18. L.M. Vrooman, J.G. Supko, and D.S. Neuberg Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia Pediatr Blood Cancer 54 2 2010 199 205
19. L.B. Silverman, J.G. Supko, and K.E. Stevenson Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia Blood 115 7 2010 1351 1353
20. R. Gray A class of K-sample tests for comparing the cumulative incidence of competing risks Ann Stat 16 1988 1141 1154
21. J. Fine, and R. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
22. J.P. Neglia, D.L. Friedman, and Y. Yasui Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study J Natl Cancer Inst 93 8 2001 618 629 (Pubitemid 32409629)
23. O. Beaty 3rd, M.M. Hudson, and C. Greenwald Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease J Clin Oncol 13 3 1995 603 609
24. B.H. Kushner, A. Zauber, and C.T. Tan Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience Cancer 62 7 1988 1364 1370
25. S. Bhatia, L.L. Robison, and O. Oberlin Breast cancer and other second neoplasms after childhood Hodgkin's disease N Engl J Med 334 12 1996 745 751 (Pubitemid 26089355)
26. G. Schellong, M. Riepenhausen, and U. Creutzig Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group J Clin Oncol 15 6 1997 2247 2253 (Pubitemid 27251125)
27. F.E. van Leeuwen, W.J. Klokman, and M. Stovall Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease J Natl Cancer Inst 95 13 2003 971 980 (Pubitemid 36896714)
28. N.J. Winick, R.W. McKenna, and J.J. Shuster Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide J Clin Oncol 11 2 1993 209 217 (Pubitemid 23046809)
29. C.H. Pui, D. Pei, and J.T. Sandlund Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia Leukemia 24 2 2010 371 382
30. V. Conter, M. Arico, and G. Basso Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia Leukemia 24 2 2010 255 264
31. W.A. Kamps, K.M. e Bruin, and A.J. Veerman Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004 Leukemia 24 2 2010 309 319
32. C. Mitchell, S. Richards, C.J. Harrison, and T. Eden Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001 Leukemia 24 2 2010 406 418
33. M. Tsurusawa, Y. Shimomura, and K. Asami Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia Leukemia 24 2 2010 335 344
34. C.H. Pui, R.C. Ribeiro, and M.L. Hancock Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia N Engl J Med 325 24 1991 1682 1687
35. J. Pedersen-Bjergaard, G. Daugaard, and S.W. Hansen Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours Lancet 338 8763 1991 359 363
36. S. Classen, S. Olland, and J.M. Berger Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 Proc Natl Acad Sci USA 100 19 2003 10629 10634 (Pubitemid 37140080)
37. P.D. Foglesong, C. Reckord, and S. Swink Doxorubicin inhibits human DNA topoisomerase I Cancer Chemother Pharmacol 30 2 1992 123 125
38. M.A. Smith, L. Rubinstein, and J.R. Anderson Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins J Clin Oncol 17 2 1999 569 577 (Pubitemid 29075244)
39. G. Germano, M. Pigazzi, and L. del Giudice Two consecutive immunophenotypic switches in a child with MLL-rearranged acute lymphoblastic leukemia Haematologica 91 Suppl. 5 2006 ECR09
40. W.L. Salzer, M. Devidas, and W.L. Carroll Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group Leukemia 24 2 2010 355 370
41. J.M. LeClerc, A.L. Billett, and R.D. Gelber Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01 J Clin Oncol 20 1 2002 237 246 (Pubitemid 34032617)
42. L.B. Silverman, K.E. Stevenson, and J.E. O'Brien Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000) Leukemia 24 2 2010 320 334
43. N. Hijiya, K.K. Ness, R.C. Ribeiro, and M.M. Hudson Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues Cancer 115 1 2009 23 35